Find Reports
Select Report Type
Reimbursement Review
Displaying 1176 - 1200 of 1422
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| omalizumab | Xolair | omalizumab | Chronic rhinosinusitis with nasal polyps | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0026-000 | |||
| mepolizumab | Nucala | mepolizumab | Asthma, severe eosinophilic (pediatric) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0027-000 | |||
| dabrafenib and trametinib | Tafinlar and Mekinist | dabrafenib and trametinib | Pediatric high-grade glioma with BRAF V600E | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0028-000 | |||
| dabrafenib and trametinib | Tafinlar and Mekinist | dabrafenib and trametinib | Pediatric low-grade glioma with BRAF V600E | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0029-000 | |||
| treosulfan | Trecondyv | treosulfan | Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0030-000 | |||
| daratumumab | Darzalex | daratumumab | Multiple myeloma, eligible for autologous stem cell transplant | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0031-000 | |||
| liraglutide | Victoza | liraglutide | Diabetes Mellitus, Type 2 (pediatric) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0032-000 | |||
| dexamethasone intravitreal imp... | Ozurdex | dexamethasone intravitreal implant | Non-infectious uveitis | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0033-000 | |||
| trastuzumab deruxtecan | Enhertu | trastuzumab deruxtecan | Metastatic HER2-positive breast cancer | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0035-000 | |||
| capmatinib | Tabrecta | capmatinib | Metastatic non-small cell lung cancer (NSCLC) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0036-000 | |||
| solriamfetol | Sunosi | solriamfetol | Excessive daytime sleepiness | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0039-000 | |||
| Fampridine | Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Withdrawn | SR0404-000 | ||||
| Vortioxetine | Trintellix | Vortioxetine | Depression, major depressive disorder | Withdrawn | SR0402-000 | ||||
| Propranolol | Hemangiol | Propranolol | Infantile hemangioma | Withdrawn | SR0411-000 | ||||
| Tedizolid phosphate | Sivextro | Tedizolid phosphate | Acute bacterial skin and skin structure infections | Withdrawn | SR0413-000 | ||||
| Palonosetron | Aloxi (capsule) | Palonosetron | Chemotherapy-induced nausea and vomiting | Withdrawn | SR0415-000 | ||||
| Eculizumab | Soliris | Eculizumab | Atypical hemolytic uremic syndrome | N/A | Complete | SF0416-000 | |||
| Pharmaceutical Reviews Update ... | |||||||||
| Acalabrutinib | Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | PC0211-000 | |||
| Nivolumab-Ipilimumab | Opdivo-Yervoy | Nivolumab-Ipilimumab | NSCLC | Reimburse with clinical criteria and/or conditions | Complete | PC0218-000 | |||
| Prostate cancer | Prostate cancer | Complete | PH0057-000 | ||||||
| Anaplastic Lymphoma Kinase (AL... | Anaplastic Lymphoma Kinase (ALK) -Positive Non-small Cell Lung Cancer (NSCLC) | Complete | PH0058-000 | ||||||
| Pharmaceutical Reviews Update ... | |||||||||
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | In Progress | PH0082-000 | ||||||
| Melanoma | Melanoma | Open for Input | PH0072-000 |
Health Technology Review
Displaying 576 - 600 of 600
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 1176 - 1200 of 2132
Please scroll or swipe to the right to view the full content.